Prodegre Pharmaceutical

Prodegre Pharmaceutical is a Shanghai-based biotechnology company founded in early 2024, specializing in the development of innovative peptide-based protein degraders. The company's lead candidate, PDR-001, is a first-in-class peptide-based protein degrader targeting alpha-synuclein for the treatment of Parkinson's disease. PDR-001 utilizes the cell's natural ubiquitin-proteasome system to degrade pathogenic proteins, representing a potential causal treatment for neurodegenerative disorders. In late 2025, Prodegre initiated an investigator-initiated trial (IIT) for PDR-001 at Ruijin Hospital in Shanghai, marking a significant milestone as the world's first peptide-based protein degrader to enter clinical testing for Parkinson's. The company leverages its proprietary peptide degradation platform to address high-unmet-need indications beyond neurology. Prodegre works closely with clinical and CRO partners, including SDM Bioservices, to accelerate the development of its pipeline.